Beta haemolytic streptococcal infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Beta haemolytic streptococcal infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants https://clinicaltrials.eu/trial/a-study-of-group-b-streptococcus-6-valent-polysaccharide-conjugate-vaccine-in-healthy-pregnant-women-and-their-infants/ Wed, 29 Apr 2026 15:07:51 +0000 https://clinicaltrials.eu/trial/a-study-of-group-b-streptococcus-6-valent-polysaccharide-conjugate-vaccine-in-healthy-pregnant-women-and-their-infants/ This study is looking at Group B streptococcus disease, which is an infection that can affect newborn babies. Group B streptococcus, often called GBS, is a type of bacteria that can be passed from mothers to their babies during pregnancy or birth. The study will use Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6), which is a vaccine designed to protect against six different types of GBS bacteria. Some pregnant women in this study will receive this vaccine while others will receive placebo. The vaccine is given as a solution for injection into the muscle.

The purpose of this study is to learn about the safety of the GBS vaccine in pregnant women and their babies, and to measure how well the vaccine helps the mother’s body create protective substances called antibodies that can be passed to the baby. These antibodies are measured to see if they could protect infants from GBS infections that can occur in the first days after birth, called early-onset disease, or infections that happen later in the first months of life, called late-onset disease. The study will look at whether the vaccine can create enough antibodies against all six types of GBS bacteria included in the vaccine.

During the study, pregnant women between 24 and 36 weeks of pregnancy will receive either the vaccine or placebo. The study will monitor the pregnant women for any reactions at the injection site such as redness, swelling, or pain, as well as general symptoms like fever, nausea, vomiting, diarrhea, headache, tiredness, muscle pain, and joint pain. Blood samples will be taken from mothers and their babies at different times to measure antibody levels. The babies will be followed after birth to check their health and safety, and to measure the antibodies they received from their mothers through the vaccine.

]]> Antibiotic Treatment with Clindamycin and Benzylpenicillin to Prevent Group G and C Streptococcal Infections in Pregnant Women https://clinicaltrials.eu/trial/antibiotic-treatment-with-clindamycin-and-benzylpenicillin-to-prevent-group-g-and-c-streptococcal-infections-in-pregnant-women/ Wed, 29 Apr 2026 15:01:53 +0000 https://clinicaltrials.eu/trial/antibiotic-treatment-with-clindamycin-and-benzylpenicillin-to-prevent-group-g-and-c-streptococcal-infections-in-pregnant-women/ This clinical trial is focused on preventing infections caused by Group G and C Streptococcus during childbirth. These bacteria can be part of the natural flora found in the vaginal and rectal areas of some pregnant women. The study aims to evaluate the effectiveness of giving antibiotics during labor to prevent infections in both the mother and the newborn. The antibiotics being studied are Clindamycin and Benzylpenicillin, which are administered through an injection or infusion.

Participants in this study are pregnant women who have been found to carry Group G or C Streptococcus in their vaginal-rectal area during routine screening in late pregnancy. The study will compare the effects of the antibiotics with a placebo to determine their effectiveness in preventing infections. The main goal is to see if these antibiotics can reduce the risk of postpartum infections in mothers and any related complications in newborns.

The study will follow participants from the time of labor through the postpartum period, which is the time after childbirth. Researchers will monitor for any infections in the mother that require antibiotic treatment up to three months after delivery. They will also observe the health of the newborn, including any need for additional medical care. The study is expected to provide valuable information on the best ways to prevent infections during and after childbirth.

]]>